INVE-A Stock Analysis: Investor ser. | ST

Asset Management | ST, Sweden | Market Cap: 1.203.048m SEK | 12M Return: 39% | Charts, Fundamentals & Technical Analysis

Private Equity, Healthcare, Financial Services, Technology, Life Sciences
Total Rating 60
Safety 25
Buy Signal 0.33
Asset Management
Industry Rotation: +5.9
Market Cap: 124B
Avg Turnover: 140M
Risk 3d forecast
Volatility16.2%
VaR 5th Pctl2.90%
VaR vs Median8.65%
Reward TTM
Sharpe Ratio1.74
Rel. Str. IBD74.3
Rel. Str. Peer Group86.5
Character TTM
Beta0.572
Beta Downside0.491
Hurst Exponent0.533
Drawdowns 3y
Max DD21.68%
CAGR/Max DD1.16
CAGR/Mean DD6.74
EPS (Earnings per Share) EPS (Earnings per Share) of INVE-A over the last years for every Quarter: "2021-06": 17.15, "2021-09": 8.8033, "2021-12": 26.46, "2022-03": -22.5527, "2022-06": -21.38, "2022-09": 2.7334, "2022-12": 16.81, "2023-03": 10.7237, "2023-06": 14.8058, "2023-09": -3.621, "2023-12": 19.56, "2024-03": 21.87, "2024-06": 21.27, "2024-09": 4.1787, "2024-12": -10.3489, "2025-03": -0.9898, "2025-06": 14.78, "2025-09": 19.52, "2025-12": 18.07, "2026-03": 9.82, "2026-06": 38.26,
EPS CAGR: 0.02%
EPS Trend: 0.0%
Qual. Beats: 0
Revenue Revenue of INVE-A over the last years for every Quarter: 2021-06: 40178, 2021-09: 37657, 2021-12: 92153, 2022-03: -57362, 2022-06: -51916, 2022-09: 22447, 2022-12: 65661, 2023-03: 46457, 2023-06: 61241, 2023-09: 2442, 2023-12: 74711, 2024-03: 82210, 2024-06: 80866, 2024-09: 26774, 2024-12: -13955, 2025-03: 11905, 2025-06: 61579, 2025-09: 75355, 2025-12: 72988, 2026-03: 25923, 2026-06: 133926,
Rev. CAGR: 2.33%
Rev. Trend: 5.5%
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Idiosyncratic Leader

Seasonality 10.5 years of data

Jan +1.6% 28
Feb -0.2% 0
Mar -0.3% 2
Apr +2.9% 30
May -0.3% 14
Jun -1.4% 29
Jul +2.0% 37
Aug -2.5% 24
Sep -0.2% 11
Oct -0.1% 5
Nov +1.6% 32
Dec -1.5% 18

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: INVE-A Investor ser.

Investor AB, founded in 1916 and headquartered in Stockholm, Sweden, is a publicly listed private equity and holding company that manages long-term investments across three categories: core investments, operating investments, and financial investments. The firm invests globally in sectors including health care, financial services, IT and fintech, life sciences, data, materials science, artificial intelligence, and quantum technology, while concentrating its operating investments in medium-sized to large companies based in Northern Europe.

Investor AB pursues both majority and minority stakes, typically investing between $200 million and $700 million per transaction, and generally holds private equity positions for three to seven years. The firm seeks board representation in its portfolio companies and has been listed on the Stockholm Stock Exchange as one of Swedens largest publicly traded investment companies, operating under a permanent-capital model that allows it to take long-duration positions in both public and private companies.

Headlines to Watch Out For
  • Atlas Copco, ABB earnings swing listed portfolio fair value
  • Patricia Industries organic growth and bolt-on M&A expand NAV
  • Annual dividend hikes and buybacks underpin long-term total returns
Piotroski VR-10 (Strict) 6.0
Net Income: 263b TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.34 > 1.0
NWC/Revenue: 7.72% < 20% (prev 45.94%; Δ -38.22% < -1%)
CFO/TA 0.02 > 3% & CFO 23.9b > Net Income 263b
Net Debt (106b) to EBITDA (267b): 0.40 < 3
Current Ratio: 2.21 > 1.5 & < 3
Outstanding Shares: last quarter (3.07b) vs 12m ago 0.03% < -2%
Gross Margin: 93.46% > 18% (prev 91.69%; Δ 1.77% > 0.5%)
Asset Turnover: 27.58% > 50% (prev 8.76%; Δ 18.82% > 0%)
Interest Coverage Ratio: 48.85 > 6 (EBIT TTM 267b / Interest Expense TTM 5.46b)
Altman Z'' 10.00
A: 0.02 (Total Current Assets 43.5b - Total Current Liabilities 19.7b) / Total Assets 1249b
B: 0.74 (Retained Earnings 925b / Total Assets 1249b)
C: 0.24 (EBIT TTM 267b / Avg Total Assets 1117b)
D: 6.65 (Book Value of Equity 1086b / Total Liabilities 163b)
Altman-Z'' = 11.13 = AAA
Beneish M 0.48
DSRI: 3.0 (Receivables 12.5b/3.00m, Revenue 308b/86.3b)
GMI: 0.98 (GM 91.69% / 93.46%)
AQI: 1.03 (AQ_t 0.95 / AQ_t-1 0.92)
SGI: 3.57 (Revenue 308b / 86.3b)
TATA: 0.19 (NI 263b - CFO 23.9b) / TA 1249b)
Beneish M = 0.48 (Cap -4..+1) = D
What is the price of INVE-A shares?

As of July 28, 2026, the stock is trading at SEK 397.90 with a total of 568,982 shares traded. Over the past week, the price has changed by +1.95%, over one month by +1.95%, over three months by +9.28% and over the past year by +39.02%.

Current recommended Stop Loss: 389.70 (which is 2.1% or 1.4 ATR below the current price).

Is INVE-A a buy, sell or hold?

Investor ser. has no consensus analysts rating.

Investor ser. (INVE-A) - Fundamental Data Overview as of 25 July 2026
Market Cap USD = 124b (1203b SEK * 0.1034 SEK.USD)
P/E Trailing = 4.5839
P/E Forward = 3.6711
P/S = 3.6677
P/B = 1.1088
P/EG = 4.9117
Revenue TTM = 308b SEK
EBIT TTM = 267b SEK
EBITDA TTM = 267b SEK
Long Term Debt = 111b SEK (from longTermDebt, last fiscal year)
Short Term Debt = 1.45b SEK (from shortTermDebt, last quarter)
Debt = 126b SEK (from shortLongTermDebtTotal, last quarter) + Leases 128.0m
Net Debt = 106b SEK (calculated: Debt 126b - CCE 19.5b)
Enterprise Value = 1310b SEK (1203b + Debt 126b - CCE 19.5b)
Interest Coverage Ratio = 48.85 (Ebit TTM 267b / Interest Expense TTM 5.46b)
EV/FCF = 63.31x (Enterprise Value 1310b / FCF TTM 20.7b)
FCF Yield = 1.58% (FCF TTM 20.7b / Enterprise Value 1310b)
FCF Margin = 6.71% (FCF TTM 20.7b / Revenue TTM 308b)
Net Margin = 85.22% (Net Income TTM 263b / Revenue TTM 308b)
Gross Margin = 93.46% ((Revenue TTM 308b - Cost of Revenue TTM 20.2b) / Revenue TTM)
Gross Margin QoQ = none% (prev 67.33%)
Tobins Q-Ratio = 1.05 (Enterprise Value 1310b / Total Assets 1249b)
Interest Expense / Debt = 4.33% (Interest Expense 5.46b / Debt 126b)
Taxrate = 0.46% (1.22b / 264b)
NOPAT = 265b (EBIT 267b * (1 - 0.46%))
Current Ratio = 2.21 (Total Current Assets 43.5b / Total Current Liabilities 19.7b)
Debt / Equity = 0.12 (Debt 126b / totalStockholderEquity, last quarter 1086b)
Debt / EBITDA = 0.40 (Net Debt 106b / EBITDA 267b)
Debt / FCF = 5.15 (Net Debt 106b / FCF TTM 20.7b)
Total Stockholder Equity = 981b (last 4 quarters mean from totalStockholderEquity)
RoA = 23.51% (Net Income 263b / Total Assets 1249b)
RoE = 26.77% (Net Income TTM 263b / Total Stockholder Equity 981b)
RoCE = 24.42% (EBIT 267b / Capital Employed (Equity 981b + L.T.Debt 111b))
RoIC = 21.84% (NOPAT 265b / Invested Capital 1216b)
WACC = 7.64% (E(1203b)/V(1329b) * Re(7.99%) + D(126b)/V(1329b) * Rd(4.33%) * (1-Tc(0.00)))
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 46.81 | Cagr: 0.01%
[DCF] Terminal Value 76.09% ; FCFF base≈20.3b ; Y1≈21.2b ; Y5≈24.4b
[DCF] Fair Price = 216.9 (EV 377b - Net Debt 106b = Equity 270b / Shares 1.25b; r=8.35% [WACC [floored]]; 5y FCF grow 5.12% → 2.50% )
EPS Correlation: 0.02 | EPS CAGR: 0.02% | SUE: N/A | # QB: 0
Revenue Correlation: 5.49 | Revenue CAGR: 2.33% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+0.5%